[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Wong  WL, Su  X, Li  X,  et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.  Lancet Glob Health. 2014;2(2):e106-e116. doi:10.1016/S2214-109X(13)70145-1PubMedGoogle ScholarCrossref
Rosenfeld  PJ, Brown  DM, Heier  JS,  et al; MARINA Study Group.  Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2006;355(14):1419-1431. doi:10.1056/NEJMoa054481PubMedGoogle ScholarCrossref
Brown  DM, Michels  M, Kaiser  PK, Heier  JS, Sy  JP, Ianchulev  T; ANCHOR Study Group.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study.  Ophthalmology. 2009;116(1):57-65.e5. doi:10.1016/j.ophtha.2008.10.018PubMedGoogle ScholarCrossref
Heier  JS, Brown  DM, Chong  V,  et al; VIEW 1 and VIEW 2 Study Groups.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.  Ophthalmology. 2012;119(12):2537-2548. doi:10.1016/j.ophtha.2012.09.006PubMedGoogle ScholarCrossref
Martin  DF, Maguire  MG, Fine  SL,  et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.  Ophthalmology. 2012;119(7):1388-1398. doi:10.1016/j.ophtha.2012.03.053PubMedGoogle ScholarCrossref
Rofagha  S, Bhisitkul  RB, Boyer  DS, Sadda  SR, Zhang  K; SEVEN-UP Study Group.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).  Ophthalmology. 2013;120(11):2292-2299. doi:10.1016/j.ophtha.2013.03.046PubMedGoogle ScholarCrossref
Varano  M, Eter  N, Winyard  S, Wittrup-Jensen  KU, Navarro  R, Heraghty  J.  Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey.  Clin Ophthalmol. 2015;9:2243-2250. doi:10.2147/OPTH.S92548PubMedGoogle ScholarCrossref
Agarwal  A, Rhoades  WR, Hanout  M,  et al.  Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.  Clin Ophthalmol. 2015;9:1001-1015.PubMedGoogle Scholar
Spaide  R.  Ranibizumab according to need: a treatment for age-related macular degeneration.  Am J Ophthalmol. 2007;143(4):679-680. doi:10.1016/j.ajo.2007.02.024PubMedGoogle ScholarCrossref
Stewart  MW.  Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? or losing?  J Clin Med. 2015;4(5):1079-1101. doi:10.3390/jcm4051079PubMedGoogle ScholarCrossref
Vardarinos  A, Gupta  N, Janjua  R, Iron  A, Empeslidis  T, Tsaousis  KT.  24-Month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.  BMC Ophthalmol. 2017;17(1):58. doi:10.1186/s12886-017-0451-1PubMedGoogle ScholarCrossref
Wykoff  CC, Croft  DE, Brown  DM,  et al; TREX-AMD Study Group.  Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results.  Ophthalmology. 2015;122(12):2514-2522. doi:10.1016/j.ophtha.2015.08.009PubMedGoogle ScholarCrossref
Wykoff  CC, Ou  WC, Brown  DM,  et al; TREX-AMD Study Group.  Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study.  Ophthalmol Retina. 2017;1(4):314-321. doi:10.1016/j.oret.2016.12.004PubMedGoogle ScholarCrossref
Wykoff  CC, Ou  WC, Croft  DE,  et al; TREX-AMD Study Group.  Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.  Br J Ophthalmol. 2018;102(4):460-464.PubMedGoogle Scholar
Rufai  SR, Almuhtaseb  H, Paul  RM,  et al.  A systematic review to assess the “treat-and-extend” dosing regimen for neovascular age-related macular degeneration using ranibizumab.  Eye (Lond). 2017;31(9):1337-1344. doi:10.1038/eye.2017.67PubMedGoogle ScholarCrossref
Kim  LN, Mehta  H, Barthelmes  D, Nguyen  V, Gillies  MC.  Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration.  Retina. 2016;36(8):1418-1431. doi:10.1097/IAE.0000000000001142PubMedGoogle ScholarCrossref
Arnold  JJ, Campain  A, Barthelmes  D,  et al; Fight Retinal Blindness Study Group.  Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration.  Ophthalmology. 2015;122(6):1212-1219. doi:10.1016/j.ophtha.2015.02.009PubMedGoogle ScholarCrossref
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group.  The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.  Ophthalmology. 2014;121(5):1092-1101. doi:10.1016/j.ophtha.2013.11.031PubMedGoogle ScholarCrossref
Silva  R, Berta  A, Larsen  M, Macfadden  W, Feller  C, Monés  J; TREND Study Group.  Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study.  Ophthalmology. 2018;125(1):57-65. doi:10.1016/j.ophtha.2017.07.014PubMedGoogle ScholarCrossref
Hatz  K, Prünte  C.  Treat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 month study.  Acta Ophthalmol. 2017;95(1):e67-e72. doi:10.1111/aos.13031PubMedGoogle ScholarCrossref
Epstein  D, Amrén  U.  Near vision outcome in patients with age-related macular degeneration treated with aflibercept.  Retina. 2016;36(9):1773-1777. doi:10.1097/IAE.0000000000000978PubMedGoogle ScholarCrossref
Chen  YN, Powell  AM, Mao  A, Sheidow  TG.  Retrospective review of Lucentis “treat and extend” patterns and outcomes in age-related macular degeneration.  Retina. 2016;36(2):272-278. doi:10.1097/IAE.0000000000000691PubMedGoogle ScholarCrossref
Rahimy  E, Rayess  N, Ho  AC, Regillo  CD.  Treatment outcomes for neovascular age-related macular degeneration patients with initial vision better than 20/40 using a treat-and-extend regime.  Retina. 2016;36(5):875-880. doi:10.1097/IAE.0000000000000814PubMedGoogle ScholarCrossref
Rayess  N, Houston  SK  III, Gupta  OP, Ho  AC, Regillo  CD.  Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.  Am J Ophthalmol. 2015;159(1):3-8.e1. doi:10.1016/j.ajo.2014.09.011PubMedGoogle ScholarCrossref
Homer  N, Grewal  DS, Mirza  RG, Lyon  AT, Gill  MK.  Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.  Eye (Lond). 2015;29(9):1152-1155. doi:10.1038/eye.2015.87PubMedGoogle ScholarCrossref
Wickremasinghe  SS, Janakan  V, Sandhu  SS, Amirul-Islam  FM, Abedi  F, Guymer  RH.  Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol.  Retina. 2016;36(7):1331-1339. doi:10.1097/IAE.0000000000000902PubMedGoogle ScholarCrossref
Barthelmes  D, Walton  R, Campain  AE,  et al; Fight Retinal Blindness! Project Investigators.  Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data.  Br J Ophthalmol. 2015;99(3):359-364. doi:10.1136/bjophthalmol-2014-305514PubMedGoogle ScholarCrossref
Berg  K, Pedersen  TR, Sandvik  L, Bragadóttir  R.  Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.  Ophthalmology. 2015;122(1):146-152. doi:10.1016/j.ophtha.2014.07.041PubMedGoogle ScholarCrossref
Wai  KM, Singh  RP.  Treat and extend dosing regimen with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.  Am J Ophthalmic Clin Trials. 2018;1(1):1-6. doi:10.25259/AJOCT-2-2018Google ScholarCrossref
Chakravarthy  U, Harding  SP, Rogers  CA,  et al.  A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-Related Choroidal Neovascularisation (IVAN).  Health Technol Assess. 2015;19(78):1-298. doi:10.3310/hta19780PubMedGoogle ScholarCrossref
Kertes  PJ, Galic  IJ, Greve  M,  et al.  Canadian Treat-and-Extend Analysis Trial With Ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian Treat-and-Extend Analysis Trial With Ranibizumab Study.  Ophthalmology. 2019;126(6):841-848. doi:10.1016/j.ophtha.2019.01.013PubMedGoogle ScholarCrossref
World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.  JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053PubMedGoogle ScholarCrossref
Ho  AC, Busbee  BG, Regillo  CD,  et al; HARBOR Study Group.  Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.  Ophthalmology. 2014;121(11):2181-2192. doi:10.1016/j.ophtha.2014.05.009PubMedGoogle ScholarCrossref
Essex  RW, Nguyen  V, Walton  R,  et al; Fight Retinal Blindness Study Group.  Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration.  Ophthalmology. 2016;123(11):2393-2400. doi:10.1016/j.ophtha.2016.07.012PubMedGoogle ScholarCrossref
Gillies  MC, Hunyor  AP, Arnold  JJ,  et al.  Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial.  JAMA Ophthalmol. 2019;137(4):372-379. doi:10.1001/jamaophthalmol.2018.6776PubMedGoogle ScholarCrossref
Gillies  MC, Alex  P, Hunyor  AP,  et al. Development of macular atrophy in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab or aflibercept using a treat-and-extend regimen: preliminary results from the RIVAL study, a randomized clinical trial. RANZCO 2018 [abstract 89]. https://ranzcoabstracts.com/abstract/development-of-macular-atrophy-in-patients-with-neovascular-age-related-macular-degeneration-namd-treated-with-ranibizumab-or-aflibercept-using-a-treat-and-extend-regimen-primary-results-from-the/. Published 2018. Accessed May 22, 2019.
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 1,295
    Citations 0
    Original Investigation
    January 9, 2020

    Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial

    Author Affiliations
    • 1The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • 2Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
    • 3Montreal Retina Institute, Montreal, Québec, Canada
    • 4Department of Ophthalmology & Visual Sciences, McGill University, Montreal, Québec, Canada
    • 5Alberta Retina Consultants, Edmonton, Alberta, Canada
    • 6Department of Ophthalmology & Visual Sciences, University of Alberta, Edmonton, Alberta, Canada
    • 7Calgary Retina Consultants, Calgary, Alberta, Canada
    • 8Department of Surgery, Section Ophthalmology, University of Calgary, Calgary, Alberta, Canada
    • 9Novartis Pharmaceuticals Canada Inc, Dorval, Québec, Canada
    • 10Ivey Eye Institute, London, Ontario, Canada
    • 11Western University, London, Ontario, Canada
    JAMA Ophthalmol. Published online January 9, 2020. doi:10.1001/jamaophthalmol.2019.5540
    Key Points

    Question  Does a treat-and-extend approach with potentially less frequent anti-vascular endothelial growth factor injections and visits provide visual outcomes not worse than monthly ranibizumab injections in patients with neovascular acute macular degeneration?

    Findings  In this randomized clinical trial of 580 patients with treatment-naive choroidal neovascularization secondary to acute macular degeneration, at month 24, visual acuity outcomes in the treat-and-extend group were not worse than those in the monthly group. This outcome occurred despite a mean of 17.6 injections and visits in the treat-and-extend group compared with 23.5 in the monthly group.

    Meaning  These 2-year outcomes, combined with those of 1-year trials, appear to support the hypothesis that treat-and-extend regimens are not worse than monthly treatment with ranibizumab for patients with neovascular acute macular degeneration similar to patients enrolled and treated in this trial.


    Importance  Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at 12 months, to date there are few data on 24-month T&E trials compared with monthly dosing.

    Objective  To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD) after 24 months.

    Design, Setting, and Participants  A randomized, open-label, multicenter, noninferiority intention-to-treat trial with a margin of −5 letters in best-corrected visual acuity (BCVA) from baseline to 12 months between groups was conducted at 27 treatment centers in Canada. Participants included 580 patients with treatment-naive choroidal neovascularization secondary to AMD. The study was conducted from May 8, 2013, to August 28, 2018, and data analysis was performed between August 29 and September 12, 2018.

    Interventions  Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab, 0.5 mg, in either a T&E or monthly dosing regimen.

    Main Outcomes and Measures  Mean change in BCVA in Early Treatment of Diabetic Retinopathy Study letters from baseline to month 24.

    Results  Of the 580 randomized patients, 350 were women (60.3%) and 547 were white (94.3%). Mean (SD) age was 78.8 (7.8) years. By the end of month 24, 466 of the 580 randomized patients (80.3%) had completed the study and participants in the T&E arm received a mean of 17.6 injections compared with 23.5 injections for the monthly arm, for a difference of 5.9 injections and visits over 2 years (95% CI, 5.4-6.5; P < .001). The mean (SD) BCVA improvement was not worse with the T&E arm, 6.8 (14.1) letters vs 6.0 (12.6) letters, compared with the monthly arm (difference, 0.9; 95% CI, −1.6 to 3.3; P = .21). There was a gain of 15 or more letters in 25.5% of the T&E group and 23.1% of the monthly treatment group (difference, 2.4%; 95% CI, −6.8% to 11.6%; P = .59) and a loss of 15 or more letters in 6.5% of the T&E group and 5.8% of the monthly treatment group (difference, −0.7%; 95% CI, −9.9% to 8.5%; P = .85).

    Conclusions and Relevance  These findings suggest that change in vision from baseline is not worse with a T&E compared with a monthly regimen of ranibizumab for nAMD through 24 months, achieving clinically meaningful improvements in BCVA despite fewer injections and visits.

    Trial Registration  ClinicalTrials.gov identifier: NCT02103738